Porter Stuart D 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Lixte (LIXT) Director Stuart D. Porter Receives RSUs
What Happened
- Stuart D. Porter, a director of Lixte Biotechnology Holdings, Inc. (LIXT), received a grant of 25,000 restricted share units (RSUs) on 2026-05-29. The grant price is reported as $0.00 (award), so there was no cash purchase or sale in this transaction. Each RSU is a contingent right to one share of common stock upon vesting.
Key Details
- Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (timely filing).
- Grant size and price: 25,000 RSUs at $0.00 (award/grant).
- Vesting: 25% vested on May 29, 2026, then 25% on the last date of each subsequent calendar quarter until fully vested.
- Plan: Granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan.
- Shares owned after transaction: not specified in the provided filing.
- Transaction type: Award/Grant (not a purchase or sale).
Context
- RSUs are a contingent right to receive shares upon vesting and subject to continued service; they do not represent immediate ownership of shares or a cash investment by the insider. Such awards are routine compensation for directors/executives and do not by themselves indicate a buying or selling signal. The eventual value depends on LIXT’s stock price at each vesting date.
Insider Transaction Report
Form 4
Porter Stuart D
Director
Transactions
- Award
Common Stock
[F1]2026-05-29+25,000→ 25,000 total
Footnotes (1)
- [F1]Represents a grant of 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs shall vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter thereafter until fully vested.
Signature
/s/ Stuart D. Porter|2026-06-01